Searchable abstracts of presentations at key conferences in endocrinology

ea0020oc1.3 | Endocrine Tumours | ECE2009

131I-Iodometomidate radiotherapy for metastatic adrenocortical carcinoma: first clinical experience

Hahner Stefanie , Kreissl Michael , Fassnacht Martin , Johanssen Sarah , Haenscheid Heribert , Reiners Christoph , Allolio Bruno , Schirbel Andreas

Subject: Treatment options for adrenocortical carcinoma (ACC) are still unsatisfactory. We could recently demonstrate that several patients with ACC exhibit a high and specific uptake of 123I-Iodometomidate (123I-IMTO). Therefore, we investigated if 131I-IMTO holds potential for radiotherapy in ACC.Methods: Dosimetry with 40 MBq I-131-IMTO was performed over 5 days in 7 patients and calculated activities were administered on a compassionate use basis in ...

ea0014oc3.5 | Endocrine tumors & neoplasia | ECE2007

[123I]Iodometomidate as a radiotracer for adrenal scintigraphy – first clinical experience

Hahner Stefanie , Stuermer Andrea , Fassnacht Martin , Kreissl Michael , Reiners Christoph , Beuschlein Felix , Zink Martina , Zolle Ilse , Schirbel Andreas , Allolio Bruno

Adrenal masses are highly prevalent tumours comprising of a variety of entities. Therefore, therapeutic consequences also vary considerably. The CYP11B-specific PET-tracer [11C]metomidate has been shown to be suitable to characterize adrenal lesions. However, its availability is restricted to PET-centers with an on-site cyclotron. Also imaging is hindered by the short tracer half-life (20 min). Therefore, we have developed [123I]iodometomidate as a tracer...

ea0041oc14.5 | Thyroid Cancer | ECE2016

Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma in Germany: a retrospective multi-center study

Wendler Julia , Kroiss Matthias , Gast Katja , Kreissl Michael , Allelein Stephanie , Lichtenauer Urs , Blaser Rainer , Kuhn Klaus , Spitzweg Christine , Fassnacht Martin , Fuhrer Dagmar , Schott Matthias , Tiedje Vera

Context: Anaplastic (ATC) thyroid carcinoma is an orphan disease accounting for about 2% of all malignant thyroid tumors. ATC confers a dismal prognosis and standard treatment is not established.Objective: To describe the epidemiology, current treatment regimens and outcome of ATC, to identify clinical prognostic markers and treatment factors associated with improved prognosis. To establish a consensus treatment schedule.Design: Re...

ea0016s30.3 | Clinical highlights | ECE2008

[123I]Iodometomidate as a radiotracer for diagnosis of adrenal tumours and adrenocortical carcinoma

Hahner Stefanie , Schirbel Andreas , Kreissl Michael , Fassnacht Martin , Johanssen Sarah , Beuschlein Felix , Quinkler Marcus , Reincke Martin , Stuermer Andrea , Reiners Christoph , Allolio Bruno

Subject: Adrenal tumours (AT) are often detected incidentally and represent a variety of differential diagnoses with variable therapeutic consequences. We have recently developed [123I]Iodometomidate ([123I]IMTO), that specifically binds to adrenal CYP11B enzymes as a SPECT tracer for adrenal scintigraphy. This radiotracer is now evaluated in patients with adrenal tumours in an ongoing clinical trial. The study was approved by the ethical committee and pa...